Study of care for babies with congenital CMV infection
Part of Infections clinical trials.
This is an observational study that looks at how babies with congenital CMV infection are diagnosed and managed in real life. It may help doctors understand which care approaches are used and how they relate to outcomes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby has congenital CMV infection confirmed by a CMV test (like PCR on urine/saliva/blood/CSF) within the first 21 days of life, or by specific older sample testing (dried blood spot, cord blood).
- The CMV diagnosis is supported by an approved test type (CMV-DNA PCR, viral culture, or similar lab confirmation).
- The child is under 11 years old.
- A parent or legal guardian can provide written informed consent.
- Both willingness to participate and eligibility are required; if consent isn’t given, the child can’t join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows women with cystic fibrosis (CF) during pregnancy and after birth, and checks on their babies and young children. The goal is to learn more about how CF affects pregnancy and child development.
This research study examines blood samples from newborns to identify biological markers (proteins and genetic signals) that could help detect and understand congenital cytomegalovirus (CMV) infection—a virus some babies are born with. Finding these markers might help doctors identify infected infants earlier and develop better treatments.
This study tests if giving antiviral medicine for 4 to 6 months helps babies born with cytomegalovirus (CMV) infection that affects their brain and development. It aims to see if longer treatment can prevent problems like hearing loss or delayed growth.
This study will follow children born in New York State who were tested for cytomegalovirus (CMV) as newborns. It aims to understand their long-term health and development, whether they were confirmed to have CMV, a false positive, or even a late detection if born early.
This Phase 2 trial tests an immune treatment made from donor T-cells to help the body fight congenital CMV infection in newborns. It may be an option if your baby is very young, has evidence of CMV infection, and meets specific blood, kidney, and liver safety limits.
This study looks at how the immune system responds to a first-time cytomegalovirus (CMV) infection during pregnancy. The goal is to find better ways to predict if the virus will pass to the baby.
Hear when a new Congenital Cmv trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.